Browse > Article

Trichostatin A, a Histone Deacetylase Inhibitor, Potentiated Cytotoxic Effect of ionizing Radiation in Human Head and Neck Cancer Cell Lines  

Kim, Jin Ho (Department of Radiation Oncology, Seoul National University College of Medicine)
Shin, Jin Hee (Department of Cancer Research Institute, Seoul National University College of Medicine)
Chie, Eui Kyu (Department of Radiation Oncology, Seoul National University College of Medicine)
Wu, Hong-Gyun (Department of Radiation Oncology, Seoul National University College of Medicine)
Kim, Jae Sung (Department of Radiation Oncology, Seoul National University College of Medicine)
Kim, Il Han (Department of Radiation Oncology, Seoul National University College of Medicine)
Ha, Sung Whan (Department of Radiation Oncology, Seoul National University College of Medicine)
Park, Charn Il (Department of Radiation Oncology, Seoul National University College of Medicine)
Kang, Wee-Saing (Department of Radiation Oncology, Seoul National University College of Medicine)
Publication Information
Radiation Oncology Journal / v.22, no.2, 2004 , pp. 138-141 More about this Journal
Abstract
Purpose : We have previously reported that human glioblastoma cells are sensitized to radiation-induced death after their exposure to trichostatin A (TSA), a histone deacetylase inhibitor (HDAC-1), prior to the irradiation. We aimed to measure the magnitude of the radiosensitizing effect of TSA in human head and neck cancer cell lines. Materials and Methods : Human head and neck cancer cell lines, HN-3 and HN-9, were exposed to 0, 50, 100, and 200 nM TSA for 18 hr prior to irradiation. Then, the TSA-treated cells were irradiated with 0, 2, 4, 6, and 8 Gy, and cell survival was measured by clonogenic assay. Results : Pre-irradiation exposure to TSA was found to radiosensitize HN-3 and HN-9 cell lines. In HN-9 cells, the fraction surviving after 2 Gy (SF2) was significantly reduced by treatment of TSA at concentration as low as 50 nM. However, a treatment with 200 nM TSA was required to significantly decrease SF2 in the HN-3 cell line. SER of pre-irradiation treatment with 200 nM TSA was 1.84 in HN-3 and 7.24 in HN-9, respectively. Conclusions : Our results clearly showed that human head and neck cancer cell lines can be sensitized to ionizing radiation by pre-irradiation inhibition of histone deacetylase (HDAC) using TSA, and that this potentiation might well be a general phenomenon.
Keywords
Trichostatin A; Histone deacelylase inhibotor; Radiosensitization; Head and neck cancer;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Li M, Luo J, Brooks CL, Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem 2002;277:50607-50611   DOI   ScienceOn
2 Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-1216   DOI   ScienceOn
3 Hoshikawa Y, Kwon HJ, Yoshida M, Horinouchi S, Beppu T. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res 1994;214:189-197   DOI   ScienceOn
4 Fournel M, Trachy-bourget M, Yan PT, et al. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res 2002;62:4325-4330   PUBMED
5 Prakash S, Foster BJ, Meyer M, et al. Chronic oral administration of CI-994: a phase 1 study. Invest New Drugs 2001;19:1-11   DOI   ScienceOn
6 Kim JH, Shin JH, Kim IH. Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys 2004;59: (in press)
7 Vaziri H, Dessain SK, Eaton EN, et al. hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase. Cell 2001;107:149-159   DOI   ScienceOn
8 Schmidt DR, Schreiber SL. Molecular association between ATR and tow components of the nucleosome remodeling and deacetylating complex, HDAC2 and CHD4. Biochem 1999;38:14711-14717   DOI   ScienceOn
9 Chung YL, Lee YHW, Yen SH, Chi KH. A novel approach for nasopharyngeal carcinoma treatment uses phenyl butyrate as a protein kinase C modulators: implications for radiosensitization and EBV-targeted therapy. Clin Cancer Res 2000;6:1452-1458   PUBMED
10 Sasakawa Y, Naoe Y, Inoue T, et al. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 2002;64:1079-1090   DOI   ScienceOn
11 Saito A, Yamashita T, Mariko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA. 1999;96:4592-4597
12 Herold C, Ganslmayer M, Ocker M, et al. The histonedeacetylase inhibitor trichostatin A block proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 2002;36:233-240   PUBMED
13 Biade S, Stobbe, CC, Boyd JT, Chapman JD. Chemical agents that promote chromatin compaction radiosensitize tumour cells. Int J Radiat Biol 2001;77:1033-1042   DOI   ScienceOn
14 Yoshida M, Beppu T. Reversible arrest of proliferation of Rat 3Y1 fibroblasts in the G1 and G2 phases by Trichostatin A. Exp Cell Res 1988;177:122-131   DOI   ScienceOn
15 Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 2001;48(Suppl. 1):20-26   DOI
16 Qui L, Kelso MJ, Hansen C, West ML, Fairlie DP, Parsons PG. Anti-tumor activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 1999;80:1252-1258   DOI   ScienceOn
17 De Ruijter AJM, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg ABP. Histone deacetylase (HDACs): characterization of the classical HDAC family. Biochem J 2003; 307:737-749
18 Kim GD, Choi YH, Dimtchev A, Jeong SJ, Dritschilo A, Jung M. Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase. J Biol Chem 1999;274:31127-31130   DOI   PUBMED
19 McBain JA, Eastman A, Nobel CS, Mueller GC. Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors. Biochem Pharmacol 1997;53:1357-1368   DOI   ScienceOn
20 Marshall JL, Rizvi N, Kauh J, et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer (Abstr.) J Exp Ther Oncol 2002;2:325-332
21 Martinez-Balbas MA, Bauer UM Nielsen SJ, Brehm A, Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J 2000;19:662-671   DOI   ScienceOn
22 Engelhard HH, Duncan HA, Kim S, Criswell PS, Van Eldik L. Therapeutic effects of sodium butyrate on glioma cells in vitro and in the rat C6 model. Neurosurgery 2001;48:616-625   DOI   ScienceOn
23 Suzuki T, Yokozaki H, Kuniyasu H, et al. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer 2000;88:992-997   DOI   ScienceOn
24 Yu X, Guo ZS Marcu MG et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002;94:504-513   DOI   PUBMED
25 Saunders N, Dicker A, Popa C, Jones S, Dahler A. Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res 1999;59:399-404   PUBMED
26 Kao GD, McKenna WG, Guenther MG, Muschel RJ, Lazar MA, Yen TJ. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J Cell Biol 2003;160:1017-1027   DOI   ScienceOn
27 Juan LJ, Shia WJ, Chen MH, et al. Histone deacetylase specifically down-regulate p53-dependent gene activation. J Biol Chem 2000;275:20436-20433   DOI   ScienceOn
28 Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim KW. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 2002;97:290-296   DOI   ScienceOn
29 Jaboin J, Wild J, Hamidi H, et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002;62:6108-6115   PUBMED
30 Tycko B, Ashkenas J. Epigenetics and its role in disease. J Clin Invest 2000;105:245-246   DOI   ScienceOn
31 Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylase, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001;98:2865-2868   DOI   ScienceOn
32 Kim SY, Chu KC, Lee HR, et al. Establishment and characterization of nine new head and neck cancer cell lines. Acta Otolaryngol (Stckh) 1997;117:775-784   DOI   ScienceOn
33 Grunstein M. Histone acetylation and chromatin structure and transcription. Nature 1997;389:349-352   DOI   PUBMED   ScienceOn
34 Yamashita Y, Shimada M, Harimoto N, et al. Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/ apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer 2003;103:572-576   DOI   ScienceOn
35 Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8:718-728   PUBMED
36 Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends Genet 2003;19:286-293   DOI   ScienceOn
37 Medina V, Edmonds B, Young GP, James R, Appleton S, Zalewski PD. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 1997;57:3697-3707   PUBMED
38 Gilbert J, Baker SD, Bowling MK, et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001;7:2292-2300   PUBMED
39 Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001;61:8492-8497   PUBMED
40 Kim YB, Yoshida M, Sueharu H. Selective induction of cyclin-dependent kinase inhibitors and their roles in cell cycle arrest caused by trichostatin A, an inhibitor of histone deacetylase. Ann N Y Acad Sci 1999;886:200-203   DOI   PUBMED
41 Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8:718-728   PUBMED
42 Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2 (promotes cell survival under stress. Cell 2001;107:137-148   DOI   PUBMED   ScienceOn
43 Chan HM, Kristic-Demonacos M, Smith L, Demonacos C, La Thangue N. Acetylation control of the retinoblastoma tumor-suppressor protein. Nat Cell Biol 2001;3:667-674   DOI   ScienceOn
44 Luo J, Su F, Chen, D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000;408:377-381   DOI   ScienceOn